Current practice in patients with differentiated thyroid cancer

Nat Rev Endocrinol. 2021 Mar;17(3):176-188. doi: 10.1038/s41574-020-00448-z. Epub 2020 Dec 18.


Considerable changes have occurred in the management of differentiated thyroid cancer (DTC) during the past four decades, based on improved knowledge of the biology of DTC and on advances in therapy, including surgery, the use of radioactive iodine (radioiodine), thyroid hormone treatment and availability of recombinant human TSH. Improved diagnostic tools are available, including determining serum levels of thyroglobulin, neck ultrasonography, imaging (CT, MRI, SPECT-CT and PET-CT), and prognostic classifications have been improved. Patients with low-risk DTC, in whom the risk of thyroid cancer death is <1% and most recurrences can be cured, currently represent the majority of patients. By contrast, patients with high-risk DTC represent 5-10% of all patients. Most thyroid cancer-related deaths occur in this group of patients and recurrences are frequent. Patients with high-risk DTC require more aggressive treatment and follow-up than patients with low-risk DTC. Finally, the strategy for treating patients with intermediate-risk DTC is frequently defined on a case-by-case basis. Prospective trials are needed in well-selected patients with DTC to demonstrate the extent to which treatment and follow-up can be limited without increasing the risk of recurrence and thyroid cancer-related death.

Publication types

  • Review

MeSH terms

  • Cell Differentiation / physiology*
  • Humans
  • Iodine Radioisotopes / administration & dosage
  • Positron Emission Tomography Computed Tomography / methods*
  • Positron Emission Tomography Computed Tomography / trends
  • Thyroid Neoplasms / diagnostic imaging*
  • Thyroid Neoplasms / metabolism
  • Thyroid Neoplasms / therapy*
  • Thyroidectomy / methods
  • Thyroidectomy / trends


  • Iodine Radioisotopes